CAR-T therapy in Acute lymphocytic leukemia
DOI:
https://doi.org/10.54097/hset.v14i.1836Keywords:
CAR-T, Therapy, CancerAbstract
Acute lymphocytic leukemia is a serious threat to people’s health. For a long time, the main therapy to cure the cancers include surgery and chemotherapy, but the traditional therapy still has some limitations and the side effect after treatment will seriously affect the quality of life. CAR-T has gradually become a new treatment to cure ALL.CAR-T cell which is through gene engineered T cell to carry the scFV. Then the engineered T cell can specific recognition the antigen and kill the tumor cell. But with the application of CAR-T, there are more and more problems show up, such as the safety, efficiency and relapse. This review discussed the mechanism and applications of CAR-T in acute lymphocytic leukemia and introduce the advantage of CAR-T and some limitations and future development.
Downloads
References
Dranoff G. et al, Leukemia-acute lymphocytic-all-statistics. Cancer.Net [J]. 2022
Mandal, D. A. Acute lymphoblastic leukemia classification. News [J]. 2019
Martino, M. et al, A review of clinical outcomes of CAR T-cell therapies for B-Acute ymphoblastic Leukemia. International Journal of Molecular Sciences [J]. 2021, 22: 2150.
dult Acute Lymphoblastic Leukemia Treatment (PDQ®)–patient version. National Cancer Institute [J]. 2022
Li, Z. et al, Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Leukemia Current Trends in Therapy for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. J Clin Hematol (China) [J]. 2022, 35:159-164.
Lim, W. A. et al, The principles of engineering immune cells to treat cancer. Cell [J]. 2017, 168: 724-740.
Benmebarek, M. R. et al, Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International journal of molecular sciences [J]. 2019, 20: 1283.
Maher, J. et al, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRΖ /CD28 receptor. Nature Biotechnology [J]. 2002, 20: 70-75.
Morgan, R. A. et al, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy [J]. 2010, 18: 843–851.
Zhang, C. et al, (2017). Engineering car-T cells. Biomarker Research [J]. 2017, 5(1).
Sterner, R. C. et al, Car-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal [J]. 2021, 11(4).
Funfrock, P. The structure of CAR-T cells. ProteoGenix [J]. 2021
Ohsu Knight Cancer Institute. OHSU. (n.d.).
Car T cells: Engineering immune cells to treat cancer. National Cancer Institute. (n.d.). 2022, Ward, M. H. et al, Residential levels of polybrominated diphenyl ethers and risk of childhood acute lymphoblastic leukemia in California. Environmental Health Perspectives [J]. 2014, 122: 1110-1116.
Greenbaum, U. et al, Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: State of the art and Future Directions. Frontiers in Oncology [J]. 2020, 10.
Sheykhhasan, M. et al, Use of car T-cell for acute lymphoblastic leukemia (ALL) treatment: A review study. Cancer Gene Therapy [J]. 2022
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
